CNR Institutional Research Information System

CARLOMAGNO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.147
NA - Nord America 746
SA - Sud America 300
EU - Europa 217
AF - Africa 17
OC - Oceania 2
Totale 2.429
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 716
SG - Singapore 507
CN - Cina 247
BR - Brasile 246
HK - Hong Kong 123
VN - Vietnam 122
FR - Francia 64
NL - Olanda 39
KR - Corea 36
AR - Argentina 26
DE - Germania 25
JP - Giappone 25
IT - Italia 23
BD - Bangladesh 21
GB - Regno Unito 20
EC - Ecuador 13
CA - Canada 12
FI - Finlandia 11
IN - India 11
ID - Indonesia 10
MX - Messico 10
IQ - Iraq 8
CO - Colombia 7
IL - Israele 6
ES - Italia 5
UA - Ucraina 5
ZA - Sudafrica 5
HN - Honduras 4
KZ - Kazakistan 4
OM - Oman 4
RU - Federazione Russa 4
AT - Austria 3
EG - Egitto 3
LB - Libano 3
LT - Lituania 3
MA - Marocco 3
PL - Polonia 3
PY - Paraguay 3
SE - Svezia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
CL - Cile 2
CZ - Repubblica Ceca 2
IE - Irlanda 2
JM - Giamaica 2
PK - Pakistan 2
SA - Arabia Saudita 2
TN - Tunisia 2
TW - Taiwan 2
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CY - Cipro 1
DZ - Algeria 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
JO - Giordania 1
KW - Kuwait 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
NP - Nepal 1
PE - Perù 1
PT - Portogallo 1
QA - Qatar 1
SR - Suriname 1
TH - Thailandia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 2.429
Salva come PNG Salva come JPEG
Città #
Santa Clara 314
Singapore 281
Hong Kong 122
Hefei 77
Beijing 61
Lauterbourg 55
Ashburn 53
San Jose 50
Ho Chi Minh City 40
Seoul 36
Hanoi 31
Los Angeles 26
Tokyo 19
São Paulo 18
Frankfurt am Main 11
Helsinki 11
New York 11
Rio de Janeiro 9
Buffalo 8
Belo Horizonte 7
Quận Bình Thạnh 7
Baghdad 6
Dhaka 6
London 6
Minamishinagawa 6
Montreal 6
Biên Hòa 5
Brasília 5
Campinas 5
Da Nang 5
Dallas 5
Denver 5
Guayaquil 5
Haiphong 5
Naples 5
Nuremberg 5
Portsmouth 5
Charlotte 4
Düsseldorf 4
Orem 4
Phoenix 4
Salvador 4
Sumaré 4
Acalanes Ridge 3
Atlanta 3
Barra do Piraí 3
Boardman 3
Chicago 3
Curitiba 3
Diadema 3
Falkenstein 3
Hangzhou 3
Johannesburg 3
José C. Paz 3
Lake Worth 3
Madrid 3
Philadelphia 3
Poplar 3
Quito 3
Rome 3
Seeb 3
Shanghai 3
Stockholm 3
São José 3
Tashkent 3
Uberaba 3
Vienna 3
Viçosa 3
Ahmedabad 2
Alexandria 2
Alfenas 2
Almaty 2
Amsterdam 2
Asunción 2
Bauru 2
Belford Roxo 2
Bengaluru 2
Camas 2
Charleston 2
Chennai 2
Cleveland 2
Diamantina 2
Douglasville 2
Dourados 2
Durban 2
El Paso 2
Hampstead 2
Harker Heights 2
Kyiv 2
Leesburg 2
Livermore 2
Magé 2
Manchester 2
Mexico City 2
Mumbai 2
Nova Serrana 2
Patos de Minas 2
Pelotas 2
Phủ Lý 2
Piracicaba 2
Totale 1.495
Salva come PNG Salva come JPEG
Nome #
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms 116
ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases. 77
Attacking cancer with molecularly targeted agents Editorial overview 68
Genetic alterations in differentiated thyroid cancer: what can be expected for gene expression profiling of thyroid carcinomas 58
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells 57
NCOA4 deficiency impairs systemic iron homeostasis 55
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. 53
NCOA4-mediated Ferritinophagy in Macrophages Is Crucial to Sustain Erythropoiesis in Mice 52
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases 51
Bioisosteric discovery of npa101.3, a second-generation ret/vegfr2 inhibitor optimized for single-agent polypharmacology 51
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. 50
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies 49
Ret gene fusions in malignancies of the thyroid and other tissues 49
Iron and ferritin modulate MHC Class i expression and NK cell recognition 48
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms 48
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology 47
Identification of novel small molecule inhibitors of oncogenic RET kinase 47
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 47
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation 45
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 45
Ret-mediated mitogenesis requires Src kinase activity 43
RET/PTC activation in human thyroid carcinomas 43
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 42
Oncogenic rearrangements driving ionizing radiation-associated human cancer 42
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation 42
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application 42
BRAF is a therapeutic target in aggressive thyroid carcinoma. 41
RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block. 41
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 40
Receptor tyrosine kinase inhibitors in thyroid cancer. 40
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose 39
Growth factor transduction pathways: Paradigm of anti-neoplastic targeted therapy 38
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. 37
Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis 36
Targeting RET Kinase in Thyroid Cancer 36
Pros and cons of cellular studies in developing new drugs for thyroid cancers. 34
Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis 34
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. 34
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. 33
Central role of RET in thyroid cancer 33
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 31
Constitutive and AP20187-induced Ret activation in photoreceptors does not protect from light-induced damage. 31
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 30
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. 29
Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential 29
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. 29
BAY 43-9006 inhibition of oncogenic RET mutants. 29
Minireview: RET: normal and abnormal functions 28
Receptor tyrosine kinases as targets for anticancer therapeutics. 26
The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 25
Glial cell line-Derived Neurotrophic Factor differentially stimulates Ret mutants associated with the Multiple Endocrine Neoplasia type 2 syndromes and Hirschsprung's disease 25
New therapeutic approaches to treat medullary thyroid carcinoma. 25
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. 24
Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): Evidence for a divergence of the ERKs and JNKs pathways induced by Ret 24
Different mutations of the RET gene cause different human tumoral diseases 24
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. 23
Molecular biology of the MEN2 gene 23
Dysfunction of the RET receptor in human cancer. 22
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein. 22
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. 21
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells 20
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B 20
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. 17
Totale 2.460
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.978
article - articoli 7.978
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.956
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202416 0 0 0 0 0 0 0 0 1 0 9 6
2024/2025998 10 3 71 32 299 35 30 51 25 60 185 197
2025/20261.391 53 215 101 212 256 72 183 83 59 85 53 19
2026/202755 55 0 0 0 0 0 0 0 0 0 0 0
Totale 2.460